Novasys gets $13 million financing:
This article was originally published in Clinica
Novasys has secured $13 million in a financing, which will enable it to continue developing an investigational, non-surgical treatment for female stress urinary incontinence. The Sunnyvale, California company recently completed the treatment of 41 women with the condition - it is currently collecting and analysing the clinical results. Novasys says that 80% of the 25 million sufferers of bladder control problems in the US are women. Stress urinary incontinence is the most common incontinence problem for women.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.